

NIH GUIDE

**For Grants
and
Contracts**

NOTICE OF MAILING CHANGE

Check here if you wish to
discontinue receiving this
publication

Check here if your address has
changed and you wish to con-
tinue receiving this publication.
Make corrections below and
mail this page to:

**NIH Guide,
Printing & Reproduction Branch
National Institutes of Health
Room B4BN08, Building 31
Bethesda, Maryland 20892**

**U.S. DEPARTMENT OF HEALTH
AND HUMAN SERVICES**

OFFICIAL BUSINESS
Penalty for Private Use, \$300

The NIH Guide announces scientific
initiatives and provides policy and
administrative information to indi-
viduals and organizations who need to
be kept informed of opportunities,
requirements, and changes in extra-
mural programs administered by the
National Institutes of Health.

**Vol. 19, No. 5
February 2, 1990**

<p>First Class Mail Postages & Fees Paid PHS/NIH/OD Permit No. G-291</p>

NOTICES

A GUIDE TO PRIORITY SCORES, PERCENTILES, AND PAYLINES 1
Division of Research Grants
Index: RESEARCH GRANTS

FLEXIBLE DURATION OF LENGTH OF SUPPORT FOR CLINICAL INVESTIGATOR
RESEARCH CAREER PROGRAM AWARDS 2
National Institutes of Health
Index: NATIONAL INSTITUTES OF HEALTH

DATED ANNOUNCEMENTS (RFPs AND RFAs)

RESEARCH PROGRAM TO MAXIMIZE THE EFFICACY OF PSYCHOTHERAPY AND DRUG
ABUSE COUNSELING STRATEGIES IN THE TREATMENT OF COCAINE ABUSERS
(RFA DA-90-01) 2
National Institute on Drug Abuse
Index: DRUG ABUSE

ONGOING PROGRAM ANNOUNCEMENTS

CENTRAL TASTE PATHWAYS AND NEUROCHEMISTRY 4
National Institute on Deafness and Other Communication Disorders
Index: DEAFNESS, COMMUNICATION DISORDERS

ACADEMIC AWARD IN SYSTEMIC AND PULMONARY VASCULAR DISEASE 5
National Heart, Lung, and Blood Institute
Index: HEART, LUNG, BLOOD

ALCOHOL RESEARCH GRANTS 6
National Institute on Alcohol Abuse and Alcoholism
Index: ALCOHOL ABUSE, ALCOHOLISM

SCHOOL-BASED PREVENTION INTERVENTION RESEARCH 8
National Institute on Drug Abuse
Index: DRUG ABUSE

SMALL GRANT PROGRAM11
National Institute on Deafness and Other Communication Disorders
Index: DEAFNESS, COMMUNICATION DISORDERS

ACADEMIC RESEARCH ENHANCEMENT AWARD13
National Institutes of Health
Index: NATIONAL INSTITUTES OF HEALTH

ERRATUM

AIDS COMMUNITY-BASED OUTREACH/INTERVENTION RESEARCH PROGRAM
(RFA DA-90-02)14
National Institute on Drug Abuse
Index: DRUG ABUSE

NOTICES

A GUIDE TO PRIORITY SCORES, PERCENTILES, AND PAYLINES

P.T. 34; K.W. 1014006

Division of Research Grants

Most of the applications submitted to NIH receive their initial review for scientific and technical merit by one of the chartered, regular study sections in the Division of Research Grants. Each application is discussed individually, and the recommendation is determined by majority vote of the members of the study section. If the application is recommended for approval, each member votes privately and individually a priority rating consistent with their assessment of its merit:

Outstanding	1.0 - 1.5	Adequate	3.0 - 3.5
Excellent	1.5 - 2.0	Fair	3.5 - 4.0
Good	2.0 - 2.5	Acceptable	4.0 - 5.0
Satisfactory	2.5 - 3.0		

The PRIORITY SCORE for an application is determined by averaging the individual ratings and multiplying by 100. Thus, the 3-digit priority scores range from 100 (best) to 500 (poorest).

To deal with the diversity of rating behavior among study sections (easy vs. hard graders) and because of priority score "creep" (an increasing proportion of scores of 150 or better), a percentile rank is now calculated for each score. The PERCENTILE represents the relative position or rank of each priority score among the scores assigned by that particular study section at its last three meetings. The lower the numerical value of the priority score or percentile, the better the application. For example, a percentile rank of 15.0 means that only 15 percent of the applications reviewed by that study section during its last three meetings had an equal or better (numerically lower) priority score. Both the priority score and the percentile rank are displayed on the summary statements forwarded to the funding unit (Institute, Center, or Division) and the applicant.

The percentile rank of priority scores now serves as the primary index of relative scientific merit when applications are being considered for funding. Although the percentile rank is extremely important, the funding decisions of an Institute, Center, or Division include other critically important factors, e.g., relevance, program goals, portfolio balance, and available funds.

When a funding unit indicates a particular PERCENTILE PAYLINE, it means that, in general, applications that have an equal or better percentile will be funded. It is important to note, however, that one CANNOT easily derive the percent of approved applications to be awarded from the percentile payline.

The AWARD RATE is the proportion of applications RECOMMENDED FOR APPROVAL that actually are awarded. In 1989, the overall award rate for research projects for all of the NIH components was 29.4 percent; this year, in fiscal year 1990, it is estimated that the overall NIH award rate will be approximately 24 percent. The award rate for any specific component may vary, depending on its appropriation.

The SUCCESS RATE is the proportion of REVIEWED applications that are actually awarded. In 1989, the overall success rate for research project applications was 27.5 percent.

As a hypothetical example, let's say that the National Back Institute (NBI) has a percentile payline of 18.0 and that among the many applications reviewed by the Biology Study Section there had been six NBI applications. If all six of those applications had percentile ranks between 0 and 18, then all six probably would be funded by the NBI. If all six had percentile ranks numerically greater than 18, then none would be funded. If only two of the six applications had percentiles between 0 and 18, and the other four had ranks greater than 18, then only two would be funded.

If there are any questions, please write to:

Director
Division of Research Grants
Westwood Building, Room 450
National Institutes of Health
Bethesda, Maryland 20892

THIS NOTICE ALSO IS BEING PUBLISHED IN PEER REVIEW NOTES.

FLEXIBLE DURATION OF LENGTH OF SUPPORT FOR CLINICAL INVESTIGATOR RESEARCH CAREER PROGRAM AWARDS

P.T. 34; K.W. 0785035, 0710030, 1014006

National Institutes of Health

The NIH is concerned that inadequate numbers of individuals with M.D.s or other professional doctorates are able to maintain a successful research career. Data indicate a strong relationship between the length of postdoctoral research training and subsequent success in receiving NIH independent research support. An analysis of professional postdoctoral trainees who subsequently became NIH grant applicants and awardees showed that the longer the period of training, the more likely an individual trainee is to apply for and receive NIH research grant support. These data indicate further that, in most cases, the period of research training and experience leading to independence extends for a period of up to five years.

Consistent with this overall five year development concept, NIH has offered Research Career Program awards, specifically the Clinical Investigator and Physician/Dental Scientist Awards, especially designed to provide research career development sufficient for professional doctorates to compete for independent NIH research support. However, it is recognized that it may be desirable to attain such independence through a combination of research experiences, including, for example, support from a National Research Service Award followed by a Clinical Investigator Award. Individuals may not need five more years for career development after completing two years in another research training environment. Therefore, flexibility in the duration of these Research Career Program awards is desirable.

For Clinical Investigator Award applications received beginning with the June 1, 1990 receipt date, applicant organizations may propose a program of development of 3, 4 or 5 years. Applicants for Physician/Dental Scientist awards who have previous research experience may propose a similarly abbreviated program of development. All applicants are advised to provide sufficient information about relevant past research experience to assure reviewers that the intended academic development could be accomplished within the proposed time frame and would likely lead to future research success.

DATED ANNOUNCEMENTS (RFPs AND RFAs)

RESEARCH PROGRAM TO MAXIMIZE THE EFFICACY OF PSYCHOTHERAPY AND DRUG ABUSE COUNSELING STRATEGIES IN THE TREATMENT OF COCAINE ABUSERS

RFA AVAILABLE: DA-90-01

P.T. 34, FF, II; K.W. 0404009, 0745060, 0770020, 0404000

National Institute on Drug Abuse

Application Receipt Date: May 23, 1990

PURPOSE: The purpose of this announcement is to support collaborative multi-site research on the efficacy of psychodynamic psychotherapy, cognitive-behavioral therapy, and drug counseling in the treatment of cocaine abusers in outpatient drug-free settings. The interaction of patient characteristics with type of treatment also will be investigated. Funds will be available under this announcement to support: (1) Collaborative Treatment Sites (CTSs) to carry out the comparative trials, and (2) a Coordinating Center (CC) to work with CTSs in the conduct of these trials. Final protocols will be developed collaboratively by a Steering Committee (SC) after awards are made.

RESEARCH OBJECTIVES: The primary research objectives are as follows: (1) is to conduct a comparative psychotherapy/drug counseling treatment efficacy study, using a common protocol, at multiple CTSs in order to compare the efficacy of different therapy approaches. (2) To define the nature of any interactions between patient characteristics (e.g., sociopathy) and success in type of therapy. (3) To support a CC to work with and support CTSs in the conduction of these comparative trials.

INCLUSION OF WOMEN IN STUDY POPULATIONS: Applicants are urged to consider the inclusion of women in the study populations for all clinical research efforts.

Exceptions would be studies of diseases which exclusively affect males or where involvement of pregnant women may expose the fetus to undue risks. Gender differences should be noted and evaluated. If women are not to be included, a clear rationale should be provided for their exclusion.

In order to provide more precise information to the treatment community, it is recommended that publications resulting from ADAMHA-supported research in which the study population was limited to one sex for any reason other than that the disease or condition studied exclusively affects that sex, should state, in the abstract summary, the gender of the population studied, e.g., "male patients," "male volunteers," "female patients," "female volunteers."

INCLUSION OF MINORITIES IN STUDY POPULATIONS: Applicants are urged to give added attention where feasible and appropriate to the inclusion of minorities in study populations for research into the etiology of diseases, research in behavioral and social sciences, clinical studies of treatment and treatment outcomes, research on the dynamics of health care and its impact on disease, and appropriate interventions for disease prevention and health promotion. If minorities are not included in a given study, a clear rationale for their exclusion should be provided.

MECHANISM OF SUPPORT: The mechanism to support these clinical trials will be a Cooperative Agreement between the awardee and NIDA. Researchers agree to accept close coordination and guidance by the SC in all aspects of the scientific and technical management of the common project, and retain primary responsibility for performance of the research, in accordance with terms formally negotiated and mutually agreed on prior to the award. Cooperative agreements are subject to the same administrative requirements as grants. All pertinent DHHS, PHS, and ADAMHA grant regulations, policies, and procedures apply. Business management aspects of these awards will be administered in accordance with DHHS and PHS grant administrative requirements.

\$2 million in first-year funds is available to support one coordinating center and 4-6 collaborative treatment sites.

REVIEW PROCEDURES: The Division of Research Grants, NIH, serves as a central point for receipt of applications. Applications received under this announcement will be assigned to a Special Review Committee (SRC) in accordance with established PHS Referral Guidelines. The SRC will review the applications for scientific and technical merit during the summer of 1990. Notification of the SRC's recommendations will be sent to the applicant after this initial review. Applications will receive a second-level review by the National Advisory Council on Drug Abuse in September 1990. Only applications recommended for approval by the Council may be considered for funding. Applications submitted in response to this announcement are not subject to the intergovernmental review requirements of Executive Order 12372, as implemented through Department of Health and Human Service regulations at 45 CFR Part 100 and are not subject to Health Systems Agency review.

APPLICATION PROCEDURES: Applicants must use the research grant application form, PHS 398 (revised 10/88). When applying, type on face page in item 2 of PHS 398, the name and number of this RFA followed by: Collaborative Treatment Site if the application is for a CTS. Type the name and number of this cooperative agreement announcement followed by Coordinating Center if the application is for a CC. If applying for both, two separate applications must be submitted. Application kits with the necessary forms and instructions (PHS 398) may be obtained from institutional business offices or offices of sponsored research of most universities, colleges and medical schools, and other major research facilities. Applications may also be obtained from: The National Institute on Drug Abuse (NIDA), Grants Management Branch, Room 8A-54, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857 (301- 443-6710).

The original and four (4) copies of applications must be submitted to:

Division of Research Grants, NIH
Westwood Building, Room 240
Bethesda, Maryland 20892**

Two copies of the application should be sent to:

Acting Director, OEPR
National Institute on Drug Abuse
5600 Fishers Lane, Room 10-42
Rockville, Maryland 20857

INQUIRES: Further information can be obtained from:

Dr. L. Onken
National Institute on Drug Abuse
5600 Fishers Lane, Room 10A-30
Rockville, Maryland 20857
Telephone: (301) 443-4060

ONGOING PROGRAM ANNOUNCEMENTS

CENTRAL TASTE PATHWAYS AND NEUROCHEMISTRY

P.T. 34; K.W. 0705070, 0710085, 1003002, 1002004, 0710100, 0710030

National Institute on Deafness and Other Communication Disorders

PURPOSE

The National Institute on Deafness and Other Communication Disorders (NIDCD) encourages submission of applications that utilize the tools, methods, and approaches of contemporary neurobiology to characterize the morphology, neurochemistry, and functional properties of central taste pathways. Of particular interest are multidisciplinary studies of pathways and neurotransmitters relevant to structure-function relations. The NIDCD wishes to support investigators at all stages of their careers, to foster a broad spectrum of research relevant to this announcement, and to encourage collaboration between investigators in and outside the field of taste and among those in various disciplines, including anatomy, biochemistry, biophysics, cell biology, neurophysiology, pharmacology, and psychophysics.

BACKGROUND

The organization of central taste pathways and associated neurotransmitters has been identified as a priority area of research by a NIDCD task force (National Institute on Deafness and Other Communication Disorders. A report of the Task Force on the National Strategic Research Plan, April 1989). Characterization of these pathways is far from complete. For example, the morphology, biophysics, and neurotransmitter properties of neuron types in the gustatory portion of the solitary nucleus have not been characterized in detail. This contrasts with more extensive knowledge about caudal regions of the solitary nucleus associated with the cardiovascular and respiratory systems, and with the refined analysis of subsets of neurons in central structures associated with other sensory systems. Whereas little is known about the gustatory neurotransmitters, pharmacological techniques are being utilized in the microdissection of the circuits of the auditory and visual systems. Opportunities exist to fill the gaps in knowledge of taste pathways with application of neurobiological techniques, including Golgi impregnation, intracellular and fluorescent markers, immunocytochemical probes, brain slice preparations, organ and tissue cultures, and other techniques that have led to advances in knowledge of the senses.

RESEARCH GOALS AND SCOPE

The research is to characterize the morphology, neurochemistry, and functional properties of central pathways with the ultimate goal of applications for effective diagnosis, treatment, and prevention of taste disorders and medical conditions associated with these disorders. Research opportunities include those that:

- o Describe central projection circuits for taste buds in various oral-pharyngeal locations.
- o Further define morphological, biophysical, and functional neuron types in taste pathways.
- o Identify the neurotransmitters and neuromodulators.
- o Characterize neurotransmitter release, reuptake, and inactivation.
- o Further examine species differences in central pathways.
- o Investigate morphological and functional changes in central circuits associated with early development, aging, and alterations in peripheral nerve input, including deafferentation.

The list of topics above is not complete; investigators are encouraged to study those or other topics that meet the objectives of this announcement.

MECHANISM OF SUPPORT

Support mechanisms include the individual research project grant (R01), First Independent Research Support and Transition Award (R29), Research Career Development Award (K04), Clinical Investigator Development Award (K08), Individual National Research Service Award (F32), and Senior Fellowship National Research Service Award (F33). The NIH policies that govern the programs will prevail. Funding is contingent upon receipt of proposals of high scientific merit, responsiveness to this announcement, relevance to the program, and availability of appropriated funds.

APPLICATION SUBMISSION AND REVIEW PROCEDURES

Application forms and kits are available from the business office or office of sponsored research of most institutions, or from the Division of Research Grants, National Institutes of Health. The application form PHS 398 (rev. 10/88) should be used to submit an application. Type "Central Taste Pathways and Neurochemistry" in item #2 of the application face page; check "YES".

Use the mailing label in the kits to mail the applications to the Division of Research Grants. Submit applications in accord with the receipt dates identified in the application kits. Applications will be reviewed as specified in the schedules of the application kits. Investigators should direct questions regarding this announcement to:

Jack Pearl, Ph.D.
National Institute on Deafness and Other Communication Disorders
National Institutes of Health
Federal Building, Room 1C-14
Bethesda, Maryland 20892
Telephone: (301) 496-5061

This program is described in the Catalog of Federal Domestic Assistance No. 13.173, Biological Research related to Deafness and Communicative Disorders. Awards will be made under the authority of the Public Health Service Act, Title IV, Section 301 (Public Law 78-410, as amended; 42 USC 241) and administered under PHS grant policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to Health Systems Agency Review.

ACADEMIC AWARD IN SYSTEMIC AND PULMONARY VASCULAR DISEASE

P.T. 34; K.W. 0705015, 0705065, 0715165, 0715135, 0715115

National Heart, Lung, and Blood Institute

Application Receipt Date: October 22, 1990

The National Heart, Lung, and Blood Institute (NHLBI) announces the availability of an Academic Award in Systemic and Pulmonary Vascular Disease. Copies of the Program Guidelines are currently available from staff of the NHLBI.

The objectives of this award are to:

1. stimulate the development and coordination of the clinical, educational, and research programs in schools of medicine or osteopathy directed toward enhancement of diagnostic and therapeutic skills in the clinical management of patients with a wide variety of vascular diseases;
2. promote professional development of the awardee so that he/she can serve as the focal point for multidisciplinary interactions promoting effectiveness in clinical care, teaching, and research in the field of vascular medicine; and
3. enable the grantee institution to continue clinical, educational, and research programs in vascular medicine once the Award is concluded.

For the purposes of this Award, vascular medicine is defined as the clinical discipline that has as its objectives: the clinical characterization of all vascular diseases (arterial, venous, lymph, cerebral, coronary, pulmonary, aortic, renal, and peripheral), the pathogenesis of these diseases (including atherosclerosis, lipid metabolic disorders, systemic and pulmonary hypertension, lymphedema, thrombosis, vasculitis, and vasospastic disorders),

as well as the diagnostic, therapeutic, and preventive approaches to these diseases.

Each school of medicine or osteopathy in the United States and its possessions or territories is eligible to compete for a nonrenewable Academic Award in Systemic and Pulmonary Vascular Disease for a project period that does not exceed five years. The Awardee must hold an M.D. or D.O. degree or their equivalent. Applications from women and minority applicants are encouraged. Only one application per institution will be accepted for review for a given receipt date. The number of new awards made each year will depend on the availability of funds.

Copies of the Program Guidelines can be obtained from:

Carol H. Letendre, Ph.D.
Associate Director for Scientific Programs
Division of Blood Diseases and Resources
National Heart, Lung, and Blood Institute
Federal Building, Room 516
Bethesda, Maryland 20892
Telephone: (301) 496-8966

David M. Robinson, Ph.D.
Associate Director for Scientific Programs
Division of Heart and Vascular Diseases
National Heart, Lung, and Blood Institute
Federal Building, Room 416
Bethesda, Maryland 20892
Telephone: (301) 496-5656

Carol Vreim, Ph.D.
Associate Director for Scientific Programs
Division of Lung Diseases
National Heart, Lung, and Blood Institute
Westwood Building, Room 6A16
Bethesda, Maryland 20892
Telephone: (301) 496-7208

The programs of the National Heart, Lung, and Blood Institute are identified in the Catalog of Federal Domestic Assistance, Number 13.837, 13.838, and 13.839. Awards will be made under the authority of the Public Health Service Act, Section 301 (42 USC 241) and administered under PHS grant policies and Federal regulations, most specifically 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or to review by a Health Systems Agency.

ALCOHOL RESEARCH GRANTS

P.T. 34; K.W. 0404003, 1003002, 1002034, 0414011, 0411005, 0745027

National Institute on Alcohol Abuse and Alcoholism

PURPOSE

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) makes grant awards for basic and applied alcohol research projects. Grant support is available to develop new knowledge in a wide range of areas relevant to alcohol abuse and alcoholism: studies of the biochemical, physiologic, and behavioral mechanisms leading to pathologic drinking behavior; studies of alcohol-induced organ damage; and studies of clinical, behavioral, and environmental factors that will lead to more effective diagnosis, prevention, and treatment techniques. Applications are encouraged for projects focused on the development and validation of new and improved treatment and intervention approaches, the reduction of alcohol-related deaths and trauma, and the prevention of alcohol-related problems and alcoholism.

RESEARCH OBJECTIVES

NIAAA provides leadership in the national effort to reduce alcoholism and alcohol-related problems. The long-range goal of the research program is to develop new knowledge that will facilitate the achievement of two broad objectives: (1) reduction of the incidence and prevalence of alcohol abuse and alcoholism; and (2) reduction of the morbidity and mortality associated with alcohol abuse and alcoholism.

NIAAA supports basic and applied research on the mechanisms of action of alcohol on biobehavioral processes and the effect of alcohol on the mind and

body. NIAAA invites applications for research grants on biomedical, behavioral, clinical, sociocultural, and epidemiological factors associated with the use or abuse of alcohol, the prevention and treatment of alcohol-related problems, and the consequences of these problems. Areas of research interest include the following general categories: Genetics and Molecular Biology; Biochemistry and Metabolism; Neuroscience; Incidence and Prevalence; Treatment; Alcohol and Pregnancy; Alcohol-Related Medical Disorders; Safety and Trauma; Behavioral and Environmental Antecedents; and Prevention.

Special attention should be paid to the need for projects which focus on alcohol-related problems of women, infants, adolescents and youth, the elderly, and minority ethnic groups.

MECHANISMS OF RESEARCH SUPPORT

Research support mechanisms include: research project grants (R01), small grants (R03), conference grants (R13), Developmental Grants for Alcoholism Treatment Assessment Research (R21), First Independent Research Support and Transition (FIRST) awards (R29), and program project grants (P01).

A list of all NIAAA program announcements and copies of specific program announcements are available by writing to the National Clearinghouse for Alcohol and Drug Information (NCADI), P.O. Box 2345, Rockville, Maryland 20852 or by calling 301-468-2600.

This announcement revises and supersedes the previous general announcement and guidelines for Alcohol Research Grants (January 1987), and incorporates announcements AA-87-02, Biological Markers of Alcohol Consumption; AA-86-04, Genetics Research on Alcoholism; and AA-86-06, Imaging Technology in Alcohol Research. This announcement also replaces announcements for research grants on the Biological Determinants of Alcohol Consumption (February 1987) and Alcohol and Endocrinological Development in Adolescents (November 1987).

ELIGIBILITY

Applications for research grants may be submitted by any public or private non-profit or for-profit institutions, such as universities, college, hospitals, laboratories, units of State and local government, and eligible agencies of the Federal Government. Women and minority investigators are encouraged to apply.

APPLICATION PROCESS

Applicants should use the grant application form PHS 398 (Rev. 10/88). The title of this announcement, "Alcohol Research Grants," should be typed in item number 2 on the face page of the PHS 398 application form. Normal application receipt dates for research grants apply.

Application kits containing the necessary forms and instructions may be obtained from business offices or offices of sponsored research at most universities, colleges, medical schools, and other major research facilities. If such a source is not available, the following office may be contacted for the necessary application material:

National Clearinghouse for Alcohol and Drug Information
P.O. Box 2345
Rockville, Maryland 20852
Telephone: (301) 468-2600

The signed original and six permanent, legible copies of the completed application should be sent to:

Division of Research Grants, NIH
Westwood Building, Room 240
Bethesda, Maryland 20892**

REVIEW PROCESS

The Division of Research Grants, NIH, serves as a central point for receipt of applications for most discretionary PHS grant programs. Applications received under this announcement will be assigned to an Initial Review Group (IRG) in accordance with established PHS Referral Guidelines. The IRGs, consisting primarily of non-Federal scientific and technical experts, will review the applications for scientific and technical merit. Notification of the review recommendations will be sent to the applicant after the initial review. Applications will receive a second-level review by an appropriate National Advisory Council whose review may be based on policy considerations as well as

scientific merit. Only applications recommended for approval by the Council will be considered for funding.

This program is described in the Catalog of Federal Domestic Assistance, No. 13.273. Grants will be awarded under the authority of Sections 301 and 510 of the Public Health Service Act, as amended (42 USC 241 and 290bb) and administered in accordance with the PHS Grants Policy Statement and Federal Regulations at 42 CFR Part 52 and 45 CFR Part 74.

This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review.

REVIEW CRITERIA

Criteria for scientific/technical merit review of applications will include the following:

- o the significance and originality from a scientific or technical standpoint of the goals of the proposed research;
- o the adequacy of the methodology proposed to carry out the research, including adequacy of experimental design for collection and analysis of data, research schematics, detailed analysis plans, and proposed instrumentations;
- o the qualifications and research experience of the principal investigator and other key research personnel;
- o the availability of adequate facilities, other resources, and collaborative arrangements necessary for the research;
- o the appropriateness of budget estimates for the proposed research activities; and
- o the adequacy of provisions for the protection of human subjects and the welfare of animal subjects, as applicable.

AWARD CRITERIA AND AVAILABILITY OF FUNDS

Applications recommended for approval by a National Advisory Council will be considered for funding on the basis of overall scientific and technical merit of the proposed research as determined by peer review, program needs and balance, and the availability of funds.

In Fiscal Year 1990, approximately \$29 million will be available to support approximately 170 new and competing continuation (i.e., renewal) grants under this announcement. The expected average amount of an award is approximately \$170,000. However, the amount of funding available will depend on appropriated funds and program priorities at the time of award.

CONSULTATION AND FURTHER INFORMATION

Potential applicants may obtain further information and consultation on program requirements by contacting the following NIAAA program staff at 5600 Fishers Lane, Rockville, Maryland 20857:

Director, Division of Basic Research
Room 14C-10
Telephone: (301) 443-2530

Director, Division of Clinical and Prevention Research
Room 16C-10
Telephone: (301) 443-1206

Chief, Epidemiology Branch
Division of Biometry and Epidemiology
Room 14C-26
Telephone: (301) 443-4897

SCHOOL-BASED PREVENTION INTERVENTION RESEARCH

P.T. 34; K.W. 0404009, 0745027, 0404000, 0725000, 0403004, 0795005

National Institute on Drug Abuse

Purpose

The purpose of this announcement is to encourage the scientific study of drug abuse prevention strategies that are based in the school environment to determine their efficacy in preventing the initiation of drug use and dependent patterns of drug use. Two major types of research are included under this announcement: innovative, theory-based, school-based programs; and, the evaluation of existing school-based programs that have been well established within schools for a number of years. Research must include both process and controlled outcome studies and must examine the relationship between process and outcome. Where possible, impact measures should be included. Process studies examine the extent to which the program has been implemented as designed. Outcome studies assess the extent to which the programs have achieved their desired effects. These studies should focus not only on drug use behaviors but also on those behavioral, attitudinal, cognitive, and environmental factors that are to be manipulated by the intervention. Finally, impact studies analyze the extent to which the programs have altered drug use practices at the school, neighborhood or community level. Follow-up analyses should emphasize the relationship between the manipulated factors and drug usage patterns.

Research Objectives

The goal of this announcement is to invite applications from researchers to study the efficacy and effectiveness of school-based interventions. Research should examine one or more of the following domains: cognitive, affective/interpersonal, behavioral, environmental, and therapeutic. Research ultimately should address the questions: What is the validity of the theoretical basis of the intervention? Does the intervention achieve the the desired effects? To what extent are these effects achieved? For whom is the intervention most effective? What process factors are associated with positive outcomes?

Although short-term studies have indicated both positive and negative results of these strategies, long-term studies need to be carried out, particularly of exposed children who may be most vulnerable to drug use and of exposed children for whom the program had the most impact. Few existing studies have examined the relationship between process and outcome. Finally, the effect of these strategies in combination with other strategies has not been assessed.

Therefore, research studies are sought that examine the relationship between these intervention strategies and drug-using behaviors with special emphasis on delineating the effects of the interventions on cognitive, behavioral, affective/interpersonal, environmental, and/or therapeutic factors and drug-using behaviors. A variety of techniques should be employed to realize the aims of these intervention approaches, including peer group discussions, special classroom activities, dissemination of policy guidelines, special parent and community organizations, and other individual and group counselling. Both the intensity and methods of these interventions need to be evaluated with respect to immediate effectiveness in intervening factors (cognitive, behavioral, affective/interpersonal, environmental and therapeutic) and to long-term drug-using behaviors.

Mechanism of Support

The mechanism of support for this announcement will be the regular research grant (R01) and FIRST Awards (R29).

Inclusion of Minorities in Study Populations

Applicants are urged to give added attention where feasible and appropriate to the inclusion of minorities in study populations for research into the etiology of diseases, research in behavioral and social sciences, clinical studies of treatment and treatment outcomes, research on the dynamics of health care and its impact on disease, and appropriate interventions for disease prevention and health promotion. If minorities are not included in a given study, a clear rationale for their exclusion should be provided.

Inclusion of Females In Study Populations

Applicants are urged to consider the inclusion of females in the study populations for all clinical research efforts that except for studies of diseases that affect males exclusively or where involvement of pregnant women may expose the fetus to undue risks. Gender differences should be noted and evaluated. If females are not to be included, a clear rationale should be provided for their exclusion.

In order to provide more precise information to the research and practitioner community, it is recommended that publications resulting from ADAMHA-sponsored research in which the study population was limited to one sex for any reason other than that the disease or condition studied exclusively affects that sex, should state, in the abstract summary, the gender of the population studied, e.g., "male subjects," "female subjects."

Review Procedures

The Division of Research Grants, NIH, serves as a central point for receipt of applications for most discretionary PHS grant programs. Applications received under this announcement will be assigned to an initial review group (IRG) in accordance with established Public Health Service Referral Guidelines. The IRG, consisting primarily of non-federal scientific and technical experts, will review the applications for scientific and technical merit. Notification of the review recommendations will be sent to the applicant after the initial review. Applications will receive a second-level review by the appropriate National Advisory Council whose review may be based on policy as well as scientific merit considerations. Only applications recommended for approval by the Council may be considered for funding.

Application Process

Applicants should use the research grant application form PHS 398 (rev. 10/88). The title of this announcement, "School-based Prevention Intervention Research", should be typed in item number 2 of the face page of the PHS 398 application form.

Application kits containing the necessary forms and instructions may be obtained from business offices or offices of sponsored research at most universities, colleges, medical schools, and other major research facilities. If such a source is not available, the following office may be contacted for the necessary application material:

Grants Management Branch
National Institute on Drug Abuse
5600 Fishers Lane, Room 8A54
Rockville, Maryland 20857
Telephone: (301) 443-6710

The signed original and six (6) permanent legible copies of the completed application should be sent to:

Division of Research Grants, NIH
Westwood Building, Room 240
Bethesda, Maryland 20892**

Applications submitted in response to this announcement are not subject to the intergovernmental review requirements of Executive Order 12372, as implemented through Department of Health and Human Services regulations at 45 CFR part 100.

Receipt and Review Schedule

The earliest receipt date for application under this announcement is April 9, 1990. For the first year only, the initial receipt date and review schedule will be as follows:

Receipt Date	Initial Review	Advisory Council Review	Earliest Start Date
Apr. 9, 1990	June/July	Sept. 1990	Sept. 1990

Thereafter, the following application receipt dates and review schedule will apply.

Receipt Dates New/Renewal	Initial Review	Advisory Council Review	Earliest Start Date
June 1/July 1*	Oct./Nov.	Jan./Feb.	Apr. 1
Oct. 1/Nov. 1*	Feb./Mar.	May/June	July 1
Feb. 1/Mar. 1*	May/June	Sept./Oct.	Dec. 1

* Amended applications (new or renewal) are to be submitted on these dates.

Applications received after a receipt date are subject to assignment to the next review cycle or may be returned to the applicant.

Review Criteria

Criteria for scientific/technical merit review of applications include the following: significance and originality from a scientific or technical standpoint of the goals of the proposed research; adequacy of the research methodology proposed to carry out the study; feasibility of the proposed research; qualifications and research experience of the principal investigator and other key research personnel; availability of adequate facilities, other resources, and collaborative arrangements necessary for the research; appropriateness of budget estimates for the proposed research activities; and adequacy of provisions for the protection of human subjects.

Award Criteria

Applications recommended for approval by the appropriate National Advisory Council will be considered for funding on the basis of overall scientific and technical merit of the research as determined by peer review, Institute program needs and balance, and availability of funds.

Further Information

Further information and consultation on program requirements relevant to prevention research can be obtained from:

Dr. Zili Amsel
Chief, Prevention Research Branch
National Institute on Drug Abuse
5600 Fishers Lane, Room 10A20
Rockville, Maryland 20857
Telephone: (301) 443-1514

SMALL GRANT PROGRAM

P.T. 34; K.W. 0715050, 0715055, 0410001, 0785055

National Institute on Deafness and Other Communication Disorders

PURPOSE

The Small Grant Program (R03) of the National Institute on Deafness and Other Communication Disorders (NIDCD) is intended to provide support for meritorious research on disorders of hearing, balance, speech, voice, language, and the chemical senses. The support is for pilot or especially innovative/high-risk research to determine the feasibility of a subsequent research project. For example, the pilot research may involve development or tests of new techniques or a small basic, clinical, or epidemiological research project.

ELIGIBILITY

The program is designed primarily to support investigators changing areas of research, especially those coming into communication disorders research for the first time from another area, and clinicians with limited research experience. Participation in the program by investigators at minority institutions is encouraged.

TERMS AND CONDITIONS OF THE AWARD

Small grant funds may not be used to supplement projects currently supported by Federal or non-Federal funds, nor to provide interim support for projects under review by the Public Health Service, nor to support thesis or dissertation research.

Applicants may request up to \$25,000 (direct costs) per year for up to two years. The grant is not renewable. Investigators are encouraged to seek continuing support for any promising research by means of an Individual Research Project Grant (R01) or a First Independent Research Support and Transition Award (R29).

APPLICATION SUBMISSION AND REVIEW PROCEDURES

The submission, review, and award schedule for the applications is:

Receipt Dates	Institute Committee Review	Council Review	Earliest Funding
September 21	Oct.-Nov.	Jan.-Feb.	March
January 21	Feb.-March	May	June
May 21	June	Sept.-Oct.	December

An NIDCD review committee will evaluate each Small Grant application with respect to these criteria: significance and scientific merit of the proposed project; its characterization as a promising or pilot project with the potential for more extended research; investigator's potential for carrying out the project; adequacy of the investigator's time commitment; adequacy of the facilities; and the justifications for budget requests. All applications will subsequently be reviewed by the National Deafness and Other Communication Disorders Advisory Council. Policies that govern grant programs of the NIH will prevail. The award of grants is contingent on receipt of proposals of high scientific merit; responsiveness to this announcement, including the eligibility of investigators; relevance to the program; and the availability of appropriated funds.

When human subjects are to be included within investigations responsive to this announcement, inclusion of underrepresented minorities, women, and individuals with disabilities is encouraged. If they are excluded, a clear rationale for their exclusion must be provided.

Use the standard research grant application forms, PHS 398 (rev. 10/88). Application kits are available from the business offices or the offices of sponsored research of most institutions or from the Division of Research Grants, National Institutes of Health. Follow the instructions in the kits with these modifications:

Grant Application (follows page 23)

Face page. Item 2. Type "Small Grant Program NIDCD". Check the "YES" box.

Page 5. Justification. Strongly and specifically justify the need for all proposed expenditures. Salary for the principal investigator will be allowed only with the strongest justifications.

Section 2

Introduction. Use an introduction for a Revised application only. Do not exceed one-half page.

Specific Aims and Significance. Do not exceed one-half page.

Progress Report/Preliminary Studies. If submitting preliminary results, do not exceed one-half page.

Methods. Do not exceed three pages.

Consortium Arrangements. Do not exceed one-half page.

Section 3

Appendix. Applicants are encouraged not to submit appendix material.

Use the mailing label in the application kit to mail the original and four copies of the application to the Division of Research Grants. To expedite the review, send one copy of the application to:

Marilyn Semmes, Ph.D.
National Institute on Deafness and Other Communication Disorders
National Institutes of Health
Federal Building, Room 9C-14
7550 Wisconsin Avenue
Bethesda, Maryland 20892
(301) 496-9223

In the event of questions, investigators are encouraged to call or write:

Jack Pearl, Ph.D.
National Institute on Deafness and Other Communication Disorders
National Institutes of Health
Federal Building, Room 1C-14
Bethesda, Maryland 20892
Telephone: (301) 496-5061

Awards will be made under the authority of the Public Health Service Act, Section 301 (Public Law 78-410, as amended; 42 USC 241) and administered under PHS grant policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. The program is not subject to Executive Order 12372.

ACADEMIC RESEARCH ENHANCEMENT AWARD

P.T. 14; K.W. 0720005, 0710030, 1014006

National Institutes of Health

Application Receipt Date: June 22, 1990

The National Institutes of Health (NIH) is making a special effort to stimulate research in educational institutions which provide baccalaureate training for a significant number of our nation's research scientists but which historically have not been major recipients of NIH support. Since Fiscal Year (FY) 1985, Congressional appropriations for the NIH have included funds for this initiative, which NIH has implemented through the Academic Research Enhancement Award (AREA) Program.

This award is designed to enhance the research environment of educational institutions that have not been traditional recipients of NIH research funds. The AREA funds are intended to support new research projects or expand ongoing research activities proposed by faculty members of these institutions in areas related to the health sciences. Applications for FY 1990 AREA grants are currently undergoing review for scientific merit. Since it is anticipated that funds will be available next year, the NIH is inviting grant applications for the FY 1991 competition for AREA grants.

Eligibility requirements of the AREA Program include the following:

Applicant Institutions

- o All domestic institutions offering baccalaureate or advanced degrees in the sciences related to health are eligible, except those that have received an NIH Biomedical Research Support Grant (BRSG) of \$20,000 or more per year for four or more years during the period from FY 1983 through FY 1989.
- o Health professional schools (e.g., schools of medicine, dentistry, nursing, osteopathy, pharmacy, veterinary medicine, public health, allied health and optometry) as well as organizationally discrete campuses of a university system, are eligible if they meet the above criterion.
- o Multiple applications proposing different research projects may be submitted by an applicant institution.

Applicant Principal Investigators

- o Must not have active research grant support (including an AREA) from either NIH or the Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA) at the applicant institution at the time of award of an AREA grant.
- o May not submit a regular NIH or ADAMHA research grant application for essentially the same project as a pending AREA application.
- o Are expected to conduct the majority of their research at their own institution, although limited access to special facilities or equipment at another institution is permitted.
- o May not be awarded more than one AREA grant at a time nor be awarded a second AREA grant to continue the research initiated under the first AREA grant.

Those in doubt about eligibility should consult their institution's Office of Sponsored Research or the Director, Special Programs and Initiatives (Building 31, Room 5B44, NIH, Bethesda, Maryland 20892, telephone (301) 496-1968).

Funding decisions will be based on the proposed research project's scientific merit and relevance to NIH programs and the institutions contribution to the undergraduate preparation of doctoral-level health professionals. Among projects of essentially equivalent scientific merit and program relevance, preference will be given to those submitted by institutions that have granted baccalaureate degrees to 25 or more individuals who, during the period

1979-1989, obtained academic or professional doctoral degrees in the health related sciences.

AREAs are awarded on a competitive basis. Applicants may request support for up to a total of \$75,000 for direct costs (plus applicable indirect costs) for a period not to exceed 36 months (maximum request \$35,000 for a single year). Although this award is non-renewable, it will enable qualified individual scientists within the eligible institutions to receive support for feasibility studies, pilot studies and other small-scale research projects preparatory to seeking more substantial funding from the regular NIH research grant programs.

Applications for this award will be accepted under the regular application submission procedures of the Division of Research Grants (DRG) of NIH. Grant applications must be prepared and submitted on Form PHS 398 (Rev. 10/88, Reprinted 9/89). Applicants must obtain the abbreviated format and simplified instructions from the Office of Grants Inquiries (see address below). These instructions must be followed in preparing an application. The receipt date is June 22, 1990.

Those individuals and institutions meeting eligibility requirements and wishing to receive further information and/or application materials should write to:

AREA
Office of Grants Inquiries
Division of Research Grants
National Institutes of Health
Westwood Building, Room 449
Bethesda, Maryland 20892
Telephone: (301) 496-7441

ERRATUM

AIDS COMMUNITY-BASED OUTREACH/INTERVENTION RESEARCH PROGRAM

RFA: DA-90-02

P.T. 34; K.W. 0715008, 0403004

National Institute on Drug Abuse

Revised Receipt Date: March 19, 1990

On Friday, January 12, 1990, the above mentioned Request for Cooperative Agreement was announced in the NIH Guide for Grants and Contracts, Vol. 19, No. 2. The receipt date announced has been changed. The NEW RECEIPT DATE FOR THIS COOPERATIVE AGREEMENT PROGRAM IS MARCH 19, 1990.

All other aspects of the announcement remain the same.

To obtain a copy of the announcement, contact the following office, identify the announcement by the name and number above.

Grants Management Branch
National Institute on Drug Abuse
Parklawn Building, Room 8A-54
5600 Fishers Lane
Rockville, Maryland 20857
Telephone: (301) 443-6710

**THE MAILING ADDRESS GIVEN FOR SENDING APPLICATIONS TO THE DIVISION OF RESEARCH GRANTS OR CONTACTING PROGRAM STAFF IN THE WESTWOOD BUILDING IS THE CENTRAL MAILING ADDRESS FOR THE NATIONAL INSTITUTES OF HEALTH. APPLICANTS WHO USE EXPRESS MAIL OR A COURIER SERVICE ARE ADVISED TO FOLLOW THE CARRIER'S REQUIREMENTS FOR SHOWING A STREET ADDRESS. THE ADDRESS FOR THE WESTWOOD BUILDING IS:

5333 Westbard Avenue
Bethesda, Maryland 20816